

**March 4, 2015**

**Information Request for BLA 125518 (original application) Imlygic™ (talimogene laherparepvec; OncoVEX<sup>GM-CSF</sup>) genetically-modified herpes simplex virus type 1 (HSV-1) encoded with hGM-CSF, as oncolytic immunotherapy for the treatment of injectable regionally or distantly metastatic melanoma.**

Please submit the proposed multicenter observational registry Study 20120139\* for pharmacovigilance under BLA 125518.

\*Previously submitted under IND 12412.